SAFETY AND EFFICACY OF AMBRISENTAN FOR THE THERAPY OF PORTOPULMONARY HYPERTENSION (POPH)

被引：0
|
作者：
Cartin-Ceba, Rodrigo [1 ]
Swanson, Karen L. [1 ]
Krowka, Michael J. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
HEPATOLOGY | 2009年 / 50卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
95
引用
收藏
页码：348A / 349A
页数：2
相关论文
共 50 条
  • [21] Ambrisentan Improves Exercise Capacity and Symptoms in Patients with Portopulmonary Hypertension
    Halank, M.
    Knudsen, L.
    Seyfarth, H. -J.
    Ewert, R.
    Wiedemann, B.
    Kolditz, M.
    Hoeffken, G.
    Hoeper, M. M.
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2011, 49 (09): : 1258 - 1262
  • [22] SAFETY OF MACITENTAN IN PORTOPULMONARY HYPERTENSION (POPH): REAL-WORLD EXPERIENCE BY LIVER TRANSPLANT CANDIDACY IN THE OPUS REGISTRY
    DuBrock, Hilary Megan
    Channick, Richard
    Kim, Nick H.
    McLaughlin, Vallerie
    Agron, Peter
    Leroy, Sandrine
    Wetherill, Graham
    Chin, Kelly
    [J]. HEPATOLOGY, 2020, 72 : 1081 - 1081
  • [23] Prediction of waitlist mortality in patients with portopulmonary hypertension (POPH): An analysis of the UNOS database
    DuBrock, Hilary M.
    Goldberg, David S.
    Sussman, Norman L.
    Bartolome, Sonja
    Kadry, Zakiyah
    Salgia, Reena
    De Wolf, Andre M.
    Mulligan, David C.
    Kawut, Steven M.
    Krowka, Michael J.
    Channick, Richard
    [J]. HEPATOLOGY, 2015, 62 : 212A - 212A
  • [24] Efficacy and Safety of Bosentan Treatment for Portopulmonary Hypertension Associated With Syncope
    Sato, Akinori
    Maie, Kouichiro
    Ohno, Yukako
    Yoshida, Tsuyoshi
    Ito, Eiichi
    Tanabe, Yasuhiko
    Aizawa, Yoshifusa
    [J]. INTERNATIONAL HEART JOURNAL, 2011, 52 (04) : 243 - 245
  • [25] LONG TERM OUTCOMES OF PORTOPULMONARY HYPERTENSION (POPH) AFTER ORTHOTOPIC LIVER TRANSPLANTATION (OLT)
    Khaderi, S. A.
    Khan, R.
    Blow, B. J.
    Safdar, Z.
    Vierling, J. M.
    Stribling, R. J.
    Goss, J. A.
    Sussman, N. L.
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S89 - S90
  • [26] Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension
    Yoshida, Shunji
    Shirato, Kunio
    Shimamura, Ryutaro
    Nakahara, Norie
    Iwase, Takayuki
    Nakajima, Hiromu
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (09) : 1827 - 1834
  • [27] Macitentan in portopulmonary hypertension (PoPH): Real-world data from OPUS and OrPHeUS
    Kim, Nick
    Chin, Kelly
    Mclaughlin, Vallerie
    Restrepo-Jaramillo, Ricardo
    Safdar, Zeenat
    Brand, Monika
    Flynn, Megan
    Leroy, Sandrine
    Morganti, Adele
    Channick, Richard
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [28] Long Term Outcomes in Patients Undergoing Orthotopic Liver Transplantation (OLT) for Portopulmonary Hypertension (POPH)
    Khaderi, Saira A.
    Khan, Rashid
    Safdar, Zeenat
    Blow, Benjamin J.
    Stribling, Rise
    Vierling, John M.
    Goss, John A.
    Sussman, Norman
    [J]. GASTROENTEROLOGY, 2013, 144 (05) : S998 - S998
  • [29] Bosentan therapy for portopulmonary hypertension
    Hoeper, MM
    Halank, M
    Marx, C
    Hoeffken, G
    Seyfarth, HJ
    Schauer, J
    Niedermeyer, J
    Winkler, J
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2005, 25 (03) : 502 - 508
  • [30] Temporal Trends in Portopulmonary Hypertension (POPH) Model for End Stage Liver Disease (MELD) Exceptions
    Del Valle, K.
    Krowka, M. J.
    Heimbach, J. K.
    Dubrock, H. M.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
12345